Differential impact of allograft rejection on kidney transplant patients with BK virus infection

Ji Won Min¹, Jae Berm Park², Jung Hwan Park³, Jong-Won Park⁴, Jaeseok Yang⁵, Curie Ahn⁶, Chul Woo Yang⁷,
Byung Ha Chung⁷

¹Division of Nephrology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea

²Department of Surgery, Samsung Medical Center, Seoul, Korea

³Division of Nephrology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea

⁴Division of Nephrology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Korea

⁵Department of Surgery, Seoul National University Hospital, Seoul, Korea

⁶Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

⁷Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Background: BK virus-associated nephropathy (BKVAN) is a known risk factor for allograft dysfunction and graft failure in kidney transplant recipients. The mainstay of treatment for BKVAN is reduction of immunosuppression and this may increase risk for acute rejection. We proposed to observe the effects of acute rejection on patients with BKVAN.

Methods: Using data from the Korean Organ Transplantation Registry, a nationwide organ transplantation database, we compared graft function, and allograft survival in BKVAN patients with or without biopsy proven acute rejection (BPAR).

Results: Among the 5,403 patients who received kidney transplantation between 2014 and June 2019, a total of 97 patients were diagnosed with BKVAN. Twenty-six patients (27%) developed BPAR within 6 months of BKVAN diagnosis, 71 patients did not. There were no differences in baseline characteristics, immunosuppression or BKVAN treatment methods between the BPAR and no BPAR groups. There was a significant decrease in allograft function in the BPAR group compared to the no BPAR group in both the 1-year (BPAR creatinine [Cr], 2.5 ± 1.9 mg/dL vs. no BPAR Cr, 1.9 ± 0.9 mg/dL; $P=0.044$) and 2-year follow-up period (BPAR Cr, 3.8 ± 3.6 mg/dL vs. no BPAR Cr, 2.2 ± 1.0 mg/dL; $P=0.015$). The BPAR group had lower allograft survival rates compared to the no BPAR group, although not statistically significant ($P=0.474$). On multivariate Cox regression analysis, MMF discontinuation was observed as a significant risk factor for rejection in BKVAN patients (hazard ratio, 4.000; 95% confidence interval [CI], 1.014–15.775; $P=0.048$).

Conclusions: Acute rejection with BKVAN is associated with poorer allograft function and survival. Also, discontinuation of MMF as treatment for BKVAN increases risk for acute rejection.

Corresponding author: Byung Ha Chung

E-mail: Chungbh@catholic.ac.kr

© The Korean Society for Transplantation

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.